Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...

An EMR-based prompt significantly boosted molecular testing rates and detection of actionable mutations in early-stage, ...

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

New targeted therapies allow for the treatment of a disease that is already the fifth leading cause of fatal tumors globally ...

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on ...

Radiomics, the extraction of quantitative features from medical images, combined with AI, showed high accuracy in predicting ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...